Mount Vernon Associates Inc. MD Buys 2,144 Shares of Teva Pharmaceutical Industries Limited (TEVA)

Mount Vernon Associates Inc. MD increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 20.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 12,460 shares of the company’s stock after buying an additional 2,144 shares during the period. Mount Vernon Associates Inc. MD’s holdings in Teva Pharmaceutical Industries Limited were worth $414,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Sii Investments Inc. WI raised its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after buying an additional 25 shares during the period. Salem Investment Counselors Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after buying an additional 32 shares during the last quarter. Cribstone Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Financial Architects Inc raised its position in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Institutional investors own 56.20% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.420% on Tuesday, reaching $32.035. 4,496,830 shares of the company’s stock were exchanged. Teva Pharmaceutical Industries Limited has a one year low of $27.60 and a one year high of $55.79. The firm has a market cap of $32.55 billion, a PE ratio of 410.705 and a beta of 0.46. The firm has a 50 day moving average price of $32.01 and a 200 day moving average price of $32.29.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the consensus estimate of $1.06. The firm had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The firm’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.20 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the stock. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $36.12 price target for the company in a research report on Monday, April 3rd. Cowen and Company reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, April 4th. BTIG Research reaffirmed a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, April 6th. Finally, CIBC reiterated a “buy” rating and issued a $43.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. Fifteen investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $42.88.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.